Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAlexandra Gomez-ArteagaMemorial Sloan Kettering Cancer CenterMNMariam T. NawasUniversity of Illinois ChicagoTOTemitope OloyedeMedical College of Wisconsin

Discussion

Loading...

Member takes

Overview

Registry study reveals TP53 alteration worsens outcomes after HCT in adverse-risk AML patients, suggesting need for better risk stratification.

Key Points

  • To assess outcomes of acute myeloid leukemia patients with TP53 alteration after allogeneic hematopoietic cell transplantation.
  • Utilized CIBMTR registry data
  • Included adults with 2017 ELN adverse risk AML
  • Stratified patients into TP53 alteration groups based on cytogenetic and molecular analysis
  • Of 6,474 patients analyzed, 703 had TP53 alteration
  • 5-yr overall survival was significantly lower in TP53 alteration groups compared to controls
  • TP53 mutation and deletion associates with higher relapse risk and worse survival outcomes

Cite This Study

Gomez-Arteaga et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d76fhttps://doi.org/10.1182/blood-2025-1060
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation2026
  2. 2Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  3. 3Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  4. 4Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT2025 · 1 citations
  5. 5Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.2025 · 1 citations